Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY26 results · Jul–Sep 2025
Solara Active Pharma Sciences reported revenue from operations of ₹313.54 crore (down 9.6% from Q2 FY25) and net loss of ₹10.10 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 313.54 | 346.95 | −9.6% | 319.15 | −1.8% |
| Other income | 0.49 | 0.32 | +53.1% | 0.98 | −50.0% |
| Total income | 314.03 | 347.27 | −9.6% | 320.13 | −1.9% |
| Profit before tax | (10.10) | 8.01 | Turned loss | 10.52 | Turned loss |
| Net profit for the period | (10.10) | 8.01 | Turned loss | 10.52 | Turned loss |
| EPS, basic (₹) | (2.36) | 2.54 | not comparable | 2.46 | Turned loss |
| Net margin (%) | -3.2 | 2.3 | 3.3 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 313.54 | 346.95 | −9.6% | 319.15 | −1.8% |
| Other income | 0.49 | 0.32 | +53.1% | 0.98 | −50.0% |
| Total income | 314.03 | 347.27 | −9.6% | 320.13 | −1.9% |
| Profit before tax | (10.08) | 8.02 | Turned loss | 10.53 | Turned loss |
| Net profit for the period | (10.08) | 8.02 | Turned loss | 10.53 | Turned loss |
| EPS, basic (₹) | (2.36) | 2.11 | not comparable | 2.46 | Turned loss |
| Net margin (%) | -3.2 | 2.3 | 3.3 |
Consolidated
- Filed with BSE
- 05 Nov 2025, 19:41 IST
- Board meeting
- 05 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Nov 2025, 19:41 IST
- Board meeting
- 05 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE